Aggressive Herpes Zoster in Young Patients With Multiple Sclerosis Under Dimethyl Fumarate: Significance of CD8⁺ and Natural Killer Cells.

IF 7.5

Neurology(R) neuroimmunology & neuroinflammation Pub Date : 2021-05-28 Print Date: 2021-07-01 DOI:10.1212/NXI.0000000000001017

Maria C Anagnostouli, Georgios Velonakis, Marinos C Dalakas

{"title":"Aggressive Herpes Zoster in Young Patients With Multiple Sclerosis Under Dimethyl Fumarate: Significance of CD8<sup>+</sup> and Natural Killer Cells.","authors":"Maria C Anagnostouli, Georgios Velonakis, Marinos C Dalakas","doi":"10.1212/NXI.0000000000001017","DOIUrl":null,"url":null,"abstract":"Dimethyl fumarate (DMF), approved for relapsing-remitting multiple sclerosis (RRMS), exerts immune-mediated mechanisms crucial for T-cell survival and migration, preferentially reducing CD8 + T cells. 1 Although baseline absolute lymphocyte count (ALC) is considered the most critical predictor of developing lymphopenia, 2 it was recently concluded that lymphocyte subset monitoring is not required for safety vigilance because T-cell subset reduction does not increase risks for serious infections. 3 We present 2 young patients with RRMS, under DMF treatment, negative for HIV and SARS-CoV-2 (by RT-PCR in nasal swab) and with normal follow-up white blood cell (WBC)/ALC counts, who developed severe herpes zoster (HZ) infection with normal ALC but low CD8 + and high CD56 bright natural killer (NK) cells, and discuss the potential signi ﬁ cance of T-cell immunophenotyping in HZ manifestation.","PeriodicalId":520720,"journal":{"name":"Neurology(R) neuroimmunology & neuroinflammation","volume":" ","pages":""},"PeriodicalIF":7.5000,"publicationDate":"2021-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/78/30/NEURIMMINFL2021038571.PMC8168045.pdf","citationCount":"4","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neurology(R) neuroimmunology & neuroinflammation","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1212/NXI.0000000000001017","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/7/1 0:00:00","PubModel":"Print","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 4

Abstract

Dimethyl fumarate (DMF), approved for relapsing-remitting multiple sclerosis (RRMS), exerts immune-mediated mechanisms crucial for T-cell survival and migration, preferentially reducing CD8 + T cells. 1 Although baseline absolute lymphocyte count (ALC) is considered the most critical predictor of developing lymphopenia, 2 it was recently concluded that lymphocyte subset monitoring is not required for safety vigilance because T-cell subset reduction does not increase risks for serious infections. 3 We present 2 young patients with RRMS, under DMF treatment, negative for HIV and SARS-CoV-2 (by RT-PCR in nasal swab) and with normal follow-up white blood cell (WBC)/ALC counts, who developed severe herpes zoster (HZ) infection with normal ALC but low CD8 + and high CD56 bright natural killer (NK) cells, and discuss the potential signi ﬁ cance of T-cell immunophenotyping in HZ manifestation.

Abstract Image